Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TEV-56278 · 1 trial · 1 indication
CTCAE: Common Terminology Criteria for Adverse Events
DLT: dose-limiting toxicity
RECIST: Response Evaluation Criteria in Solid Tumors.
| Arm | Type | Description |
|---|---|---|
| TEV-56278 Monotherapy; Dose Escalation | EXPERIMENTAL | - |
| TEV-56278 Monotherapy; Dose Expansion | EXPERIMENTAL | - |
| TEV-56278 in Combination with Pembrolizumab; Dose Escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TEV-56278 | DRUG | Administered intravenously |
| Pembrolizumab | DRUG | Administered intravenously |
Inclusion Criteria: * Have an established histological diagnosis of selected solid tumor and must have received and progressed on established standard therapies or have been intolerant to such therapy or have been considered by the Investigator as ineligible for approved standard therapy * Have a l...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
TEV-56278 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently being evaluated in a Phase 1 clinical trial in patients with advanced or metastatic solid tumors, both as a monotherapy and in combination with pembrolizumab.
The specific molecular target of TEV-56278 has not been disclosed in the available information. It is a small molecule therapeutic being studied for its anti-tumor activity in advanced solid tumors, but its mechanism of action has not been publicly detailed.
TEV-56278 is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker symbol TEVA. The company is conducting the Phase 1 clinical trial to evaluate the safety and anti-tumor activity of the drug.
TEV-56278 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is a dose escalation and expansion study assessing the drug alone or in combination with pembrolizumab.
TEV-56278 is being studied in a single Phase 1 clinical trial registered as NCT06480552. This open-label trial is evaluating the safety and anti-tumor activity of TEV-56278 alone or in combination with pembrolizumab in participants with advanced or metastatic solid tumors. The trial is currently recruiting participants in the United States and Canada.
No, TEV-56278 is not the same as pembrolizumab. TEV-56278 is an investigational small molecule developed by Teva, while pembrolizumab is an established immunotherapy drug. The ongoing clinical trial is studying TEV-56278 both alone and in combination with pembrolizumab to evaluate their combined anti-tumor activity.